🔗 Share this article

Elected officials have issued warnings that the United Kingdom's negotiated accords with Washington are "built on sand." This stems from revelations that a so-called "milestone" deal on medicines, which commits to zero tariffs in exchange for the NHS facing higher prices, lacks any detailed agreement beyond broad headline terms contained within government press releases.

An Agreement in Principle Only

The deal on drug tariffs, hailed as a "landmark" achievement, is still an "statement of intent" without detailed provisions. It has been highlighted that the official announcements from the UK and US governments describe the deal in sharply different terms. The British version focuses on securing "zero per cent tariffs" as a unique achievement, while the American announcement concentrates on the expectation for the NHS to pay significantly more for new medications.

"The danger exists that the UK government has promised concessions to raise drug prices in return for only a pledge from President Trump," stated David Henig, a trade policy analyst. "It is documented he has a record of not following through on agreements."

Broader Instability and a Paused Tech Deal

Anxieties have been amplified by Washington's recent decision to suspend the £31bn "tech prosperity deal", which was previously heralded as "a transformative pact" in the bilateral relationship. The US pointed to a lack of progress from the UK on reducing other tariffs as the reason for the pause.

Additionally, concessions secured for British farmers as part of an initial accord have not been formally ratified by the US, despite a fast-approaching January deadline. "Our understanding is that the US has failed to approve the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Uncertainty Among Officials

In confidential discussions, ministers have expressed concerns that the government's US-UK accords are lacking substance. One minister was quoted as stating the series of agreements as "resting on shaky ground," while another characterized the situation as the "new normal" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, a senior MP on the health committee, remarked: "What is even more astonishing than Trump's temper tantrums is the UK government's naive belief that his administration is a good faith actor. The NHS is too precious to be gambled with."

A Mixed Picture of Success and Setback

Ministry sources have downplayed the chances of the US backing out of the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been pushing for the agreement, wanting clarity on imports and pricing, making it of tangible value than the paused tech deal.

Officials acknowledge that instability is a feature of dealing with the current US leadership. However, they maintain that the UK has secured concrete outcomes for businesses, such as reduced duties on automobiles compared to other nations. "Securing 25% steel tariffs, which is better than the rate for the rest of the world, is not flimsy," one official said.

Yet, delays have surfaced in implementing the broader trade deal. Promised reciprocal agricultural allowances have failed to be approved, and the assurance to "remove tariffs on British steel and aluminium" has remains unmet, with tariffs remaining at 25%.

As negotiations continue, the two sides have planned to recommence talks on the suspended digital agreement in January, following what were described as "constructive" meetings between UK and US officials in Washington.